Crizotinib (PF-02341066)

For research use only.

Licensed by Pfizer Catalog No.S1068

334 publications

Crizotinib (PF-02341066) Chemical Structure

CAS No. 877399-52-5

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.

Selleck's Crizotinib (PF-02341066) has been cited by 334 publications

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.
Targets
ROS1 [6]
(Cell-free assay)
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
<0.025 nM(Ki) 11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL1 MmrzR5l1d3SxeHnjJGF{e2G7 NFjNWIZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXS2GSFyxJINmdGy|IHX4dJJme3OrbnegRWxMKGOxZYjwdoV{e2mwZzDOVG0hf2m2aDDJR|UxKG:oIECuNFEh|ryP M3iz[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
BAF3 NET3eHpEgXSxdH;4bYMhSXO|YYm= NVXW[4RuPDhiaB?= M2\FPWROW09? M4e5bmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNE43OiEQvF2= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MkW4PUc,OjF3N{K1PFk9N2F-
BAF3 M1nycGN6fG:2b4jpZ{BCe3OjeR?= MXu0PEBp NIDwUY9FVVOR M135dmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MkW4PUc,OjF3N{K1PFk9N2F-
BAF3 NVu3NW95S3m2b4TvfIlkKEG|c3H5 NIfYVHQ1QCCq M3\5VGROW09? M1TyV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyC5aYToJGlEPTBib3[gNE4zQCEQvF2= NWPBOJVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1O|I2QDlpPkKxOVczPTh7PD;hQi=>
Kelly NInZUIdEgXSxdH;4bYMhSXO|YYm= M1vIb2ROW09? NHzIZ4pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBM\WyueTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjR{IN88US=> M1mxUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
SH-SY5Y M2XVN2N6fG:2b4jpZ{BCe3OjeR?= M1j2eGROW09? NHi1boJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy|IHX4dJJme3OrbnegRWxMKEZzMUe0UEBufXSjboSge4l1cCCLQ{WwJI9nKDBwNUOg{txO NHvPXJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NlU5QSd-MkG1O|I2QDl:L3G+
SMS-KCN NX;OVYRMS3m2b4TvfIlkKEG|c3H5 MV3EUXNQ NXzvXG55S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW02VLVvDUkBk\WyuczDlfJBz\XO|aX7nJGFNUyCUMUK3OXEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkmxJO69VQ>? Mk\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{K1PFkoRjJzNUeyOVg6RC:jPh?=
BAF3 NXvU[ItUS3m2b4TvfIlkKEG|c3H5 M4HPTFQ5KGh? NEHWenJFVVOR NX[4N2FES3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIGTlcE1CVEtid3n0bEBKSzVyIH;mJFAvOTlizszN MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MkW4PUc,OjF3N{K1PFk9N2F-
3T3 NHqzcYNHfW6ldHnvckBCe3OjeR?= MXOxJIg> MmC1SG1UVw>? NWXRSodsUW6qaXLpeIlwdiCxZjDSU24h[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFgh|ryP M3HhWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFE1Lz5{MUixNlQyPDxxYU6=
3T3-E NXPxW4VVTnWwY4Tpc44hSXO|YYm= M1;iblEhcA>? MVLEUXNQ MVvJcohq[mm2aX;uJI9nKFSLRUKgZZN{\XO|ZXSg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvPDR6IN88US=> NVjrSnVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NVI1OTRpPkKxPFEzPDF2PD;hQi=>
A549 MUDLbY5ie2ViQYPzZZk> NWT1elcyOSCq NWDGSWpZTE2VTx?= NEnHSlNKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHOtUWVVKGurbnHz[UBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJT0ZvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByODFOwG0> NFjrd5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixNlQyPCd-MkG4NVI1OTR:L3G+
BAF3-BCL MY\GeY5kfGmxbjDBd5NigQ>? Mk\lNUBp MXXEUXNQ MnL1TY5pcWKrdHnvckBw\iCDQlygZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDFwMUW5JO69VQ>? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
HEK293 NU\4XJY6TnWwY4Tpc44hSXO|YYm= MXqxJIg> MmTjSG1UVw>? NGPtb5FKdmirYnn0bY9vKG:oIFHYUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6yPVQh|ryP MknrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
HEK293 MljYSpVv[3Srb36gRZN{[Xl? Mlz3NUBp NGTzNHBFVVOR NHrmPXpKdmirYnn0bY9vKG:oIFnSJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lki4O{DPxE1? M{jRUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFE1Lz5{MUixNlQyPDxxYU6=
Jurkat NFPK[npHfW6ldHnvckBCe3OjeR?= Mn\ENUBp NWCzd21{TE2VTx?= NFPWPIdKdmirYnn0bY9vKG:oIFzDT{Bie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj63OFEh|ryP MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
KARPAS299 MkPVT4lv[XOnIFHzd4F6 NGXQWpMyKGh? MWfEUXNQ NXjleYJrUW6qaXLpeIlwdiCxZjDBUGsh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NVnTS|ZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NVI1OTRpPkKxPFEzPDF2PD;hQi=>
PAE Mk\oSpVv[3Srb36gRZN{[Xl? M4LCelEhcA>? MoTPSG1UVw>? NEnQVJhKdmirYnn0bY9vKG:oIGTST2Ih[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuN|k6KM7:TR?= NIKxPXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixNlQyPCd-MkG4NVI1OTR:L3G+
PAE MnfnSpVv[3Srb36gRZN{[Xl? MWexJIg> MXzEUXNQ MXzJcohq[mm2aX;uJI9nKFSUS1GgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNUig{txO NGX2NGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixNlQyPCd-MkG4NVI1OTR:L3G+
BAF3 MXfGeY5kfGmxbjDBd5NigQ>? M4\EPFIuOyCm MVrEUXNQ NF6yTWdKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS54NEOg{txO NWL4bmdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO|QzOjV{PD;hQi=>
BAF3 NFixVWxHfW6ldHnvckBCe3OjeR?= MWOyMVMh\A>? NGnjNVlFVVOR NWL2b4pOUW6qaXLpeIlwdiCxZjDOVG0u\nW|ZXSgRWxMKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhOiC2bzCzJIRigXNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6KHerdHigTWM2OCCxZjCwMlE2ODhizszN NHHzT5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0NlI2Oid-MkO3OFIzPTJ:L3G+
BAF3 NUC4W2N6TnWwY4Tpc44hSXO|YYm= M1HhW|IuOyCm NUL4W2dHTE2VTx?= MknQR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{Bi\nSncjCyJJRwKDNiZHH5d{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmge4l1cCCLQ{WwJI9nKDNwNEe5JO69VQ>? NUjveIMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO|QzOjV{PD;hQi=>
KARPAS299 MV7DfZRwfG:6aXOgRZN{[Xl? MWSyMVMh\A>? M4fR[2ROW09? MkXGTWM2OD1yLkC2OFIh|ryP NIPFSpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0NlI2Oid-MkO3OFIzPTJ:L3G+
EBC1 M{W5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq3NkBp NFHPc|NFVVOR MUDJR|UxRTBwMEKzJO69VQ>? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
HCT116 NFzFbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHnO|IhcA>? NX7jV5R4TE2VTx?= M1jGcmlEPTB;MUSuPFIh|ryP MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
MCF7 NVPMU5F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL1PIs4OiCq NEXFRpdFVVOR M2L6[WlEPTB;OT61PEDPxE1? MmjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ|OUmzN|I5RC:jPh?=
MDA-MB-231 MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfzXmk4OiCq NHy2XGJFVVOR MU\JR|UxRTFyLkig{txO MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
MKN45 NIn5OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrzTGF5PzJiaB?= M{e1NmROW09? NG\6W2VKSzVyPUCuNFE{KM7:TR?= MoCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ|OUmzN|I5RC:jPh?=
NCI-H441 M3[5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWS3NkBp NWXTT2dETE2VTx?= NHnCbHNKSzVyPUG3MlI2KM7:TR?= NHLDN209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m5N|MzQCd-MkO5PVM{Ojh:L3G+
NCI-H661 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDNO|IhcA>? MomwSG1UVw>? MVjJR|UxRTFzLkS3JO69VQ>? NYS4fFFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
SK-MEL-28 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnPO|IhcA>? M1zhPGROW09? NVnqVoR{UUN3ME2xNE46PyEQvF2= Ml\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ|OUmzN|I5RC:jPh?=
SKOV3 M2\GWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr0O|IhcA>? NWX1OnR3TE2VTx?= MYjJR|UxRTF{Lki1JO69VQ>? NYnRUJhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
SNU5 NX;ZUIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn3O|IhcA>? M4DTNWROW09? MXXJR|UxRTBwMEG2JO69VQ>? Mn25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ|OUmzN|I5RC:jPh?=
Antiproliferative assay M{SwfmVDSzF? M1jJ[|czKGi{cx?= NGXadGRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFXCR|Eh[2WubIOg[ZhxemW|c3nu[{BmdGW4YYTl[EBt\X[nbIOgc4Yh[2:wc4TpeJV1cX[nbImgZYN1cX[nIHOtUYV1KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjB3MzFOwG0v NEnYN2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki2N|UzQSd-MkK4OlM2Ojl:L3G+
Function assay NIj2S45MSVKSQWOyPVk> MYi3NkBpenN? NUD4bIMxUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gT2FTWEGVMkm5JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiR3zvJIF{e2G7LDDJR|UxKD1iMD6wOlIh|ryPLh?= M2rCSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay MmDGUmlJNTOWMx?= M{PTUFEhcHJ? NXHlUo5uUW6qaXLpeIlwdiCxZjDoeY1idiC5aXzkJJR6eGViRV3MOE1nfXOnZDDBUGsh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJIFnfGW{IEGgbJIh[nlic3Hu[Jdq[2hiRVzJV2EtKEmFNUCgQUAxNjB6IN88UU4> NFfyd4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N|I6ODl:L3G+
Function assay NYLlfJd6VkOLLVizNVIz M2jXbFczKGi{cx?= MYjJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldkBIdG9iYYPzZZktKEmFNUCgQUAxNjFyODFOwG0v NHXUTGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N|I6ODl:L3G+
Function assay NVrPeXZnVkOLLViyNlI5 M4H3cFczKGi{cx?= MoTpTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwJF0hOC5zMUig{txONg>? MlTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay MYXOTWguO1R| NULBS2hCOSCqch?= MmC0TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDGNVE4PExibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkG2OUDPxE1w MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR|MkmwPUc,OjR2M{K5NFk9N2F-
Function assay NX7nOWg3VkmKLUPUNy=> MkHENUBpeg>? MnL1TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDDNVE2PllibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkS3PEDPxE1w M1SwelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay NGPpSGlPUUhvM2Sz MlrLNUBpeg>? M3HRc2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS|EzPjmDIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR|UxKD1iMD62NFUh|ryPLh?= NX;JOldkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay NGC1RZJPS0lvSEOxNlI> NVTEV3l5PzJiaILz MUTJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDHNVI3QUFibYX0ZY51KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwJF0hOC54MkOg{txONg>? NFHW[XY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N|I6ODl:L3G+
Function assay MoTXUmlJNTOWMx?= NEH4[moyKGi{ NFfxNnhKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJHMyOjB4WTDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuOlI3KM7:TT6= M4PHbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay MUDOR2kuUDNzMkK= Mn7OO|IhcHK| NXe2Z481UW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshVDFzOU\NJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{IFfsc{Bie3OjeTygTWM2OCB;IECuPFM5KM7:TT6= Ml\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay M4C5Z25KUC1|VEO= Ml3YNUBpeg>? MoSwTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE6Pk1ibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLki0N{DPxE1w NUfH[HkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay MYHOTWguO1R| NHXJfW0yKGi{ NGDp[21KdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTV{UjDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IEGuNFI3KM7:TT6= NXjLdnU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay MYrOTWguO1R| NYHCSmFbOSCqch?= NVrHTJJQUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW|c3XkJIlvKG2xdYPlJG5KUC1|VEOgZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXygZYZ1\XJiMTDodkBjgSC|YX7ke4lkcCCHTFnTRUwhUUN3MDC9JFMvODN7IN88UU4> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR|MkmwPUc,OjR2M{K5NFk9N2F-
Function assay MYDCRWY{ M4S0b|czKGi{cx?= M3zieWlvcGmkaYTpc44hd2ZiTmDNM2FNUyBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliW{PIYU11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwMEWxJO69VS5? M3iyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NE[4OlMzLz5{NES2PFY{OjxxYU6=
Function assay NXO0cFFvSkGIMx?= MmrhO|IhcHK| M2\MSGlvcGmkaYTpc44hd2ZiTmDNM2FNUyBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliW{PIYU11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwMEWxJO69VS5? MmnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2Nki2N|IoRjJ2NE[4OlMzRC:jPh?=
Function assay NETpfJlDSUZ| MnHKO|IhcHK| MVzJcohq[mm2aX;uJI9nKE6STT;BUGshVDFzOU\NJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIITyZY5{\mWldHXkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgX|NJZS22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OCB;IECuNlYh|ryPLh?= NHrXfmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES2PFY{Oid-MkS0Olg3OzJ:L3G+
Cytotoxicity assay NFzR[W9DSUZ| NHLISGQ4OiCqcoO= NYjmSnVPS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliW{PIYU11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwOUig{txONg>? NVTiWHp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0Olg3OzJpPkK0OFY5PjN{PD;hQi=>
Antiproliferative assay MWrOTWgwO1R| MWm3NkBpenN? MknVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDjdol7d3SrbnniMZJme2m|dHHueEBud3W|ZTDOTWgwO1R|IHPlcIx{KGijcnLvdolv\yCHTVy0MWFNUyC4YYLpZY51KDFiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEm1OEDPxE1w NX\CR3RZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFU1PjVpPkK0O|g2PDZ3PD;hQi=>
Antiproliferative assay NYLscHNLW1WSLV2y MYS3NkBpenN? Mmm2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVWCtUVIh[2WubIOgbIFz[m:{aX7nJG5RVS2DTFugZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVc1KM7:TT6= M2\mRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i1OFY2Lz5{NEe4OVQ3PTxxYU6=
Antiproliferative assay NWfyRWRKVkmKL{PUNy=> NHvSUJI4OiCqcoO= NW\2XGF4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBkemm8b4TpcoljNXKnc3nzeIFvfCCvb4Xz[UBPUUhxM2SzJINmdGy|IHjhdoJwemmwZzDFUWw1NUGOSzD2ZZJq[W62IEGvUFEyQT[PIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC54ME[g{txONg>? NUPBTWhHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFU1PjVpPkK0O|g2PDZ3PD;hQi=>
Function assay Ml3nUmlJNTOWMx?= M3j0OlEhcHJ? NUTkPZdKUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgbJVu[W5iRV3MOE1nfXOnZDDBUGsh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJIFnfGW{IEGgbJIh[nlic3Hu[Jdq[2hiRVzJV2EtKEmFNUCgQUAxNjB6IN88UU4> NYL6R3lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay MVnOTWguO1R| MoLXNUBpeg>? M3;nd2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR|UxKD1iMD6xOlUh|ryPLh?= NUfWN|BMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay NUPWfFRpVkmKLUPUNy=> NVHBOog{OSCqch?= Mo\JTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDDNVE2PllibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkS3PEDPxE1w M33XV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay NU\K[|RkVkmKLUPUNy=> M3P0WFEhcHJ? MlzSTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVI3QUFibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLk[wOUDPxE1w NXX0dZlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay MWXOTWguO1R| M3rUZlEhcHJ? NVzyW|ZMUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDpckBud3W|ZTDOTWguO1R|IHPlcIx{KGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlYzPiEQvF2u NFPMXmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
Function assay M4XZfm5KUC1|VEO= NEPob|MyKGi{ NIi2XXdKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuPFQ{KM7:TT6= NXjKS4k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay MlrZUmlJNTOWMx?= MXyxJIhz MVXJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVUzWiCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywh[W[2ZYKgNUBpeiCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDFwMEK2JO69VS5? M4\2NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay NIHaTYdPUUhvM2Sz M2niXVEhcHJ? MVXJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlAzWiCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywh[W[2ZYKgNUBpeiCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDFwMUS4JO69VS5? NEHvWFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
Function assay M2HNTW5KUC1|VEO= MlLMNUBpeg>? M3TWVmlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugNVE2OVSrboOgcZV1[W62IHX4dJJme3OnZDDpckBud3W|ZTDOTWguO1R|IHPlcIx{KGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCzMlA{QSEQvF2u NXzxcWpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay MXjNT245PDV? MWGxJIhz NHzqc4VKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOU056NEWgZ4VtdHNiYX\0[ZIhOSCqcjDifUB4\XO2ZYLuJIJtd3S2aX7nMEBKSzVyIE2gNE4xOiEQvF2u M{joSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO|UxLz5{NEmwNFc2ODxxYU6=
Function assay M{jrUG1MVjh2NR?= MnP1PVAhdWmwcx?= NELKVWVKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOU056NEWgZ4VtdHNiYX\0[ZIhQTBibXnud{BjgSCVYX7ke4lkcC2HTFnTRUwhUUN3MDC9JFAvODJizszNMi=> NIm0bHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFc2OCd-MkS5NFA4PTB:L3G+
Function assay MWDrZZJx[XNiMkm5 NVm0fGhwQTBibXnudy=> M1:xO2lvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{BxcG:|cHjvdplt[XSrb36gLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hcHWvYX6gb4FzeGG|IEK5PUBk\WyuczDh[pRmeiB7MDDtbY5{KGK7IGPhcoR4cWOqLVXMTXNCNCCLQ{WwJF0hOC5zMTFOwG0v MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEe1NEc,OjR7MEC3OVA9N2F-
Cytotoxicity assay M17BcW5EUS2KMUm5Ny=> M3LUfVQ5KGi{cx?= M1jMXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUm5N{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6wOlEh|ryPLh?= Mmq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N|AoRjJ2OUCwPFMxRC:jPh?=
Cytotoxicity assay MXTOTWgwO1R| MWG0PEBpenN? M3z3eWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJG5KUC9|VEOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwM{[0JO69VS5? NHTEcGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
Cytotoxicity assay NVP4UHJpSTV2OR?= M{nLd|Q5KGi{cx?= MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC0MlA5PCEQvF2u M4rrbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFMxLz5{NEmwNFg{ODxxYU6=
Cytotoxicity assay MYjOR2kuUDF7N{W= MYq0PEBpenN? NEXuNY9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEG5O|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEeuOVUyKM7:TT6= NF\RVZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
Antiproliferative assay NEPtV4tGSkNz NGLYbGU4OiCqcoO= MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHPNSXQu[W2ybHnmbYVlKGi3bXHuJGVDSzFiY3XscJMh[W[2ZYKgO|IhcHK|LDDJR|UxKD1iMD6wNFY6KM7:TT6= NXXTe2dwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzFpPkK0PVAxQDNzPD;hQi=>
Antiproliferative assay MUfLRXJRSVN{OUm= NF\XUFM4OiCqcoO= NF[yNHVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUy2mZYDlcoRmdnRiaIXtZY4hU0GUUFHTNlk6KGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMjFOwG0v NHHlWXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OSd-MkS5NFA5OzF:L3G+
Antitumor assay M4rQZ2JCTjN? M{KxWVUxKG2pL3vn M4W3TFIhf2Wna4O= M4HONWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOg[ZhxemW|c3nu[{BGVUx2LVHMT{BnfXOrb36gdJJwfGWrbjDhcIxw\3KjZoTl[EBqdiCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUxKG2pL3vnMEBxdyCzZDDmc5IhOiC5ZXXrd{Bz\WyjdHn2[UB1dyC4ZXjpZ4xmNXS{ZXH0[YQh[2:wdILvcC=> NWrmVpQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzFpPkK0PVAxQDNzPD;hQi=>
Antiproliferative assay Mnr2SWJEOQ>? M1;3V|czKGi{cx?= M2j2[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjB{MTFOwG0v NYTaVXdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N|c2OzBpPkK1OVM4PTNyPD;hQi=>
Antiproliferative assay MkC1V25WPQ>? MXi3NkBpenN? MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOQVUWgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4xOjB2IN88UU4> M1T6NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC1OVI{Lz5{NkCwOVUzOzxxYU6=
Antiproliferative assay NH3MU3JGSkNz M{P3OlczKGi{cx?= MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWEQ{GgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4xOjF6IN88UU4> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNUWyN{c,OjZyMEW1NlM9N2F-
Antiproliferative assay NVXoc4Q1VUuQNEW= M2S0flczKGi{cx?= NU\p[m1USW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNT241PSClZXzsd{Bi\nSncjC3NkBpenNuIFnDOVAhRSByLkCzPFEh|ryPLh?= NF7wRVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVUzOyd-Mk[wNFU2OjN:L3G+
Antiproliferative assay NIC1boJDSUZ|L2TQVk1O\XR? MoGxO|IhcHK| Moq3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQV[zM3RRWi2PZYSgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4yOjd2IN88UU4> NIi2UIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVUzOyd-Mk[wNFU2OjN:L3G+
Antiproliferative assay MlnXUmNKNUh|MUKy MUe3NkBpenN? MnrpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDBUGsu\GWyZX7k[Y51KGi3bXHuJG5EUS2KM{GyNkBk\WyuczDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjJ4MUKg{txONg>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5Nke0PUc,OjZ2N{[3OFk9N2F-
Antiproliferative assay MYXOR2kuUDNzMkK= MXy3NkBpenN? M{fOeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIFz1cYlv\XOlZX70JGNmdGxiVnnhZoltcXS7IFHzd4F6NCCHQ{WwJF0hOC5yM{Kg{txONg>? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay NXj6WHVNSmFxRkO= Ml;FO|IhcHK| NHXvT|VKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1NUGOSzCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyIE2gNE4xPTZizszNMi=> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay NVXEZXJ3SmFxRkO= NITpUJA4OiCqcoO= MV7Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0MWFNUyBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMD6wOVYh|ryPLh?= NXjRZW5zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay MV;CZU9HOw>? M4i5d|czKGi{cx?= NGH2NFJKdmirYnn0bY9vKG:oIFXNUFQuSUyNIGOxNlA3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwME[1JO69VS5? MnPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Function assay MnOyRoEwTjN? MW[3NkBpenN? NIX6fohKdmirYnn0bY9vKG:oIFXNUFQuSUyNIF[xNVc1VCCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMEixJO69VS5? NFe0eJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Function assay NG[xRXlD[S:IMx?= Mn;VO|IhcHK| NHnLVFFKdmirYnn0bY9vKG:oIFXNUFQuSUyNIFOxNVU3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMUS0JO69VS5? M2e4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay NXnkephIW02VLVvDUnI> NEW2UHI4OiCqcoO= NIi3eGxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPNV{1MS06UIHPlcIx{KGW6cILld5NqdmdiRV3MOE1CVEtiUkGyO|VSKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCOdX3pcoV{[2WwdDDD[YxtKF[rYXLpcIl1gSCDc4PhfUwhTUN3MDC9JFAvOTd7IN88UU4> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Antiproliferative assay MnuwT4VtdHl? MojPO|IhcHK| NVG5bVRVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDL[YxtgSClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKEZzMUe0UEBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO|YYmsJGVEPTBiPTCwMlIyOSEQvF2u MmDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay M2fmd2xCVjV? NUHN[lR6PzJiaILz NHfp[WlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzBUlUh[2WubIOg[ZhxemW|c3nu[{BGVUx2LVHMT{BTOTJ5NWGgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR|UxKD1iMD6yN|Ih|ryPLh?= M2nnfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay M4LV[2RHS0l5Nh?= M1W0[VczKGi{cx?= M33kTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRF\DTVc3KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshVDFzNULSJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuNlM{KM7:TT6= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay NFi4UpFD[S:IMx?= NIjmbVU4OiCqcoO= NIj2NnNKdmirYnn0bY9vKG:oIFXNUFQuSUyNIFexNlAzWiCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwM{K4JO69VS5? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Antiproliferative assay MUnTT{1PNVOK MofmO|IhcHK| NGnzcWlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW4uW0hiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCIMUG3OGwhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG|c3H5MEBGSzVyIE2gNE4{PyEQvF2u NIX0TYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay M17HSmNJVEF{MB?= M3zF[lczKGi{cx?= NFLj[IZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPIUGEzOCClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKFJzMke1VUBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO|YYmsJGVEPTBiPTCwMlQ{QSEQvF2u NYP5SWFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay M3L5TGJiN0Z| MnnYO|IhcHK| M3zac2lvcGmkaYTpc44hd2ZiRV3MOE1CVEtiR{GyOllCKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC53MUKg{txONg>? NFfyUVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay NFW3XFJUUC2VWUXZ MoLMO|IhcHK| Ml7DRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSD3TXVV[KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshTjFzN{TMJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuOVI{KM7:TT6= M4m2O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Function assay M2\aNWJiN0Z| MmnaO|IhcHK| M2frXGlvcGmkaYTpc44hd2ZiRV3MOE1CVEtiTEGxPVZOKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC53NEmg{txONg>? M2H1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Function assay NInCfJFD[S:IMx?= MlTuO|IhcHK| M3O2fmlvcGmkaYTpc44hd2ZiRV3MOE1CVEtiTEGxOVJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC54NEWg{txONg>? NI\LOlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay MnfoV2suVi2ERTiyLS=> M{njfFczKGi{cx?= NVzVTZpESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNUKHKEKpJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGVOVDRvQVzLJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG|c3H5MEBGSzVyIE2gNE44OSEQvF2u NYrGbnBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay NXGwd2RISmFxRkO= M3vNeVczKGi{cx?= MlLCTY5pcWKrdHnvckBw\iCHTVy0MWFNUyBzMUWxWIlveyCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwOEW3JO69VS5? MkPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Cytotoxicity assay MnHTRmEwTjN? MXi3NkBpenN? NVzufWFRS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwOUK3JO69VS5? MnTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay MmK1UGFPOQ>? Mlf5O|IhcHK| MnSzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOQV6xJINmdGy|IHX4dJJme3OrbnegSW1NPC2DTFugSlEyPzSOIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDFwM{S2JO69VS5? NFXlRoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay MWTTT{1PNU[L NH7Y[FY4OiCqcoO= NVTPU5RFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNU[LIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR|UxKD1iMT60Olkh|ryPLh?= NY\1cHhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Antiproliferative assay MV7TT{1PNUGV MomzO|IhcHK| M1HkfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1CWyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDFwNEezJO69VS5? MmCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay MUPESmNKOTF2 MYe3NkBpenN? MlTjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGRlPJNVE1KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshTzF{NknBJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IEGuOlE2KM7:TT6= MmnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay M3\UVWVDSzF? Mn\0O|IhcHK| NFPvRotCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFXCR|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFE6KM7:TT6= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ7OEWzOkc,OjZ4OUi1N|Y9N2F-
Cytotoxicity assay MlHPSWJEOQ>? MojLO|IhcHK| MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCLQ{WwJF0hOC5yNESg{txONg>? M1XaZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEG3OVQ5Lz5{N{CxO|U1QDxxYU6=
Antiproliferative assay M4DX[2tCWlCDU{K5PS=> M37oflczKGi{cx?= MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuDUmDBV|I6QSClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDN0OFSz24JIF{e2G7LDDJR|UxKD1iMD6xNFMh|ryPLh?= MlLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Antiproliferative assay MXPTWXAuVTJ? NHTPcpg4OiCqcoO= M1voPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XQMW0zKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLkGxNkDPxE1w NY\1UXZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN|ExPjZpPkK3NVMyODZ4PD;hQi=>
Antiproliferative assay NVPJTYlrW1VvRFjMNS=> NEfHZ484OiCqcoO= MlexRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVT3ETGwyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLkGzOkDPxE1w Mon5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Antiproliferative assay MVHOR2kuUDNzMkK= NXjKS5R{PzJiaILz NWnGPFY5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQj;DR2suQCCjc4PhfUwhUUN3MDC9JFAvOjFizszNMi=> MojZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Function assay MXTOR2kuUDNzMkK= M4jjS|czKGi{cx?= NY\5UHh3UW6qaXLpeIlwdiCxZjDBUGsh\XiycnXzd4VlKGmwIHj1cYFvKE6FST3IN|EzOiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLkK2NUDPxE1w NFTVWpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN|ExPjZ:L3G+
Antiproliferative assay NWP4WIg3VkmKL{PUNy=> MVW3NkBpenN? NWnSZpE5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDOTWgwO1R|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjJ6MzFOwG0v NFnsXpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN|ExPjZ:L3G+
Antiproliferative assay MlO5UmlJNzOWMx?= M2Cw[VczKGi{cx?= MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKE6LSD:zWFMh[2WubIOg[ZhxemW|c3nu[{BGVUx2LVHMT{BNOTF7NjDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KFOUQj;DR2suQCCjc4PhfUwhUUN3MDC9JFEvOTZizszNMi=> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|MUC2Okc,OjdzM{GwOlY9N2F-
Antiproliferative assay NGLnW2FCVEtvcH;zbZRqfmViS1HSVGFUOjl7 NYriZnBXPzJiaILz NV;RPHl[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBUGsueG:|aYTpeoUhU0GUUFHTNlk6KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzKDl4IHHxeYVwfXNib37lJJNwdHW2aX;uJINmdGxicILvcIln\XKjdHnvckBie3OjeTygTWM2OCB;IECuN|Y2KM7:TT6= NETuT4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G0OFg{OSd-MkexOFQ5OzF:L3G+
Antiproliferative assay MUjBUGsudmWpYYTpeoUhXTl|Nx?= MnGyO|IhcHK| M3XBUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQVzLMY5m\2G2aY\lJHU6OzdiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiOU[gZZF2\W:3czDvcoUhe2:udYTpc44h[2WubDDwdo9tcW[ncnH0bY9vKGG|c3H5MEBKSzVyIE2gNk4zQDZizszNMi=> M1ntUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUS0PFMyLz5{N{G0OFg{OTxxYU6=
Cytotoxicity assay MUDI[ZBIOg>? NXzzN3VFPzJiaILz MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy55IN88UU4> M2X2flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{m2PVI6Lz5{N{O5OlkzQTxxYU6=
Cytotoxicity assay NF3yO4JOUUGSYVPhNi=> NITLeWc4OiCqcoO= NITQTVhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOUUGSYVPhNkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gO{4yPiEQvF2u MoHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|OU[5NlkoRjJ5M{m2PVI6RC:jPh?=
Cytotoxicity assay NUO2U4tWUEOFOEK3 NHrTR3A4OiCqcoO= NUTvW5duS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOFOEK3JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC3MlI2KM7:TT6= NIDBfmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O5OlkzQSd-MkezPVY6Ojl:L3G+
Cytotoxicity assay NVrKU4pvU0GUUFHTNlk6 M4rB[|czKGi{cx?= NID1eJFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSVKSQWOyPVkh[2WubIOgbIFz[m:{aX7nJG5RVS2DTFugZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6wOlgh|ryPLh?= MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2N{S5NlUoRjJ5NEe0PVI2RC:jPh?=
Cytotoxicity assay MWXIR2M4QA>? NHXJXWw4OiCqcoO= MlT5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNEPzhiY3XscJMhcGG{Yn;ybY5oKFOOQ{O0RVIuWk:VMTDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkO0JO69VS5? MoXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2N{S5NlUoRjJ5NEe0PVI2RC:jPh?=
Antiproliferative assay MYPTWU1FUExz NInMWWw4OiCqcoO= M4LkTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRWxMKGOxboP0bZR2fGm4ZXz5JIFkfGm4YYTl[EBpfW2jbjDTWU1FUExzIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvODl{MzFOwG0v NGfZbHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVYzOyd-Mke3Olk3OjN:L3G+
Antiproliferative assay M4T2NG5EUS2KM{GyNi=> MmXLO|IhcHK| NGHGS4FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUyClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhcHWvYX6gUmNKNUh|MUKyJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwMUCwPUDPxE1w MnWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5Nkm2NlMoRjJ5N{[5OlI{RC:jPh?=
Antiproliferative assay M2DPVGtCWlCDU{K5PS=> NIDaR3U4OiCqcoO= NF3pb49CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUyClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhcHWvYX6gT2FTWEGVMkm5JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwMUC0PUDPxE1w M3X4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[5OlI{Lz5{N{e2PVYzOzxxYU6=
Function assay Moi3UmlJNzOWMx?= M2DPfWlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJG5KUC9|VEOgZ4VtdHNuIFnDOVAhRSByLkC4JO69VS5? NF;iSFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N|E{PDB:L3G+
Function assay NX;RdJA{VkmKL{PUNy=> MVLJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R|IHPlcIx{NCCLQ{WwJF0hOC5yODFOwG0v M4fyUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN|QxLz5{OESzNVM1ODxxYU6=
Function assay MlPTUmlJNzOWMx?= NI\iRYpKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDGNVE4PExibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjF4NTFOwG0v MlLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN|QxRC:jPh?=
Function assay MmTsUmlJNzOWMx?= NUDUW2t4UW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugSlEyPzSOIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R|IHPlcIx{NCCLQ{WwJF0hOC5zNkWg{txONg>? NID4bVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N|E{PDB:L3G+
Function assay MVXOTWgwO1R| M13Tb2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIFOxNVU3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM|NVOyClZXzsd{whUUN3MDC9JFAvPDd6IN88UU4> NGHSN4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N|E{PDB:L3G+
Function assay MXzOTWgwO1R| Mk\3TY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiQ{GxOVZ[KG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNE41PzhizszNMi=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay NELkeJVPUUhxM2Sz NHvzZXhKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDHNVI3QUFibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjZyNTFOwG0v M3nYS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN|QxLz5{OESzNVM1ODxxYU6=
Function assay NHvyb3NPUUhxM2Sz Ml3aTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiR{GyOllCKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNE43ODVizszNMi=> NETGO3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N|E{PDB:L3G+
Function assay NHPkV3RPUUhxM2Sz NGjsPYdKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDTNVIxPllibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjZ{NjFOwG0v MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay MUfOTWgwO1R| NFPlem1KdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDTNVIxPllibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjZ{NjFOwG0v M4mwcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN|QxLz5{OESzNVM1ODxxYU6=
Function assay M{DISm5KUC9|VEO= NGTTc5FKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDMNVE6Pk1ibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjh2MzFOwG0v Ml:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN|QxRC:jPh?=
Function assay NGnCW|RPUUhxM2Sz M3LDfmlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIFyxNVk3VSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM|NVOyClZXzsd{whUUN3MDC9JFAvQDR|IN88UU4> NX71ZXgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay NWr5TYZTVkmKL{PUNy=> MXvJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyCOMUG1NnIhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKE6LSD:zWFMh[2WubIOsJGlEPTBiPTCxMlAzPiEQvF2u M4LKPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN|QxLz5{OESzNVM1ODxxYU6=
Function assay NFzie|dPUUhxM2Sz NGjtV|JKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDMNVE2OlJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAyNjB{NjFOwG0v MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay Mn3nUmlJNzOWMx?= NHvNTIZKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDHNVIxOlJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAyNjF2ODFOwG0v NUO3WZQ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay MXfOTWgwO1R| MVfJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyCJMUKwNnIhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKE6LSD:zWFMh[2WubIOsJGlEPTBiPTCxMlE1QCEQvF2u MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay MlrXUmlJNzOWMx?= MW\Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyBzMUWxWIlveyCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM|NVOyClZXzsd{whUUN3MDC9JFMvODN7IN88UU4> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay Mn\2UmlJNzOWMx?= MmPZTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiMUG1NXRqdnNibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUA{NjB|OTFOwG0v NXf2enY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|E{PDBpPkK4OFMyOzRyPD;hQi=>
Cytotoxicity assay M3LaZ2VDSzF? MmTlO|IhcHK| NGjmXYZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBGSkNzIHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFZXzsJHRqfGW{LVfsc{Bie3OjeTygRYN1cX[rdImgQUAxNjBzMzFOwG0v M{LvOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W1OlM2Lz5{OEe1OVY{PTxxYU6=
Cytotoxicity assay NGe5eHdOU052NR?= MUS3NkBpenN? M2XvbWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1MVjR3IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFZXzsJHRqfGW{LVfsc{Bie3OjeTygRYN1cX[rdImgQUAxNjB{MjFOwG0v M1ez[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W1OlM2Lz5{OEe1OVY{PTxxYU6=
Cytotoxicity assay MkLiVGM{ NYfjPWppPzJiaILz NHnMZlBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KEOnbHygWIl1\XJvR3zvJIF{e2G7LDDBZ5Rqfmm2eTC9JFIvOjR2IN88UU4> NVXyXGFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OVU3OzVpPkK4O|U2PjN3PD;hQi=>
Function assay NVrYXo8{SkGIMx?= NEDld3E4OiCqcoO= MlnnTY5pcWKrdHnvckBw\iCHTVy0MYZ2e2WmIFHMT{ApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSUZ|IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODByMzFOwG0v NVfqNFduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVA6OjJpPkK4PFUxQTJ{PD;hQi=>
Function assay MknkRmFHOw>? NYLi[nk2PzJiaILz NH;4WlRKdmirYnn0bY9vKG:oIF7QUU1nfXOnZDDBUGshMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>? NHm1N3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Function assay M4\LPGJCTjN? MXm3NkBpenN? NHfqWWdKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDBUGshMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>? M1HMOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWwPVIzLz5{OEi1NFkzOjxxYU6=
Antiproliferative assay NHP5TlRPS0lvSEOxNlI> NFHEN3U4OiCqcoO= M3rTbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCHTVy0MYZ2e2WmIFHMT{B3[XKrYX6xJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBIUTVyIE2gNE4xOzdizszNMi=> MkfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Antiproliferative assay M1LzNm5EUS2KMkKyPC=> NH3SbHU4OiCqcoO= MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INlIzQCClZXzsd{Bp[XKkb4LpcochTU2OND3meZNm\CCDTFugeoFzcWGwMzDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNFc{KM7:TT6= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Function assay MWPCRWY{ M3vjSVczKGi{cx?= M3fR[mlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6xOUDPxE1w MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Function assay NGHIU3JDSUZ| NXjDUph1PzJiaILz NXTJZmlsUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBCVEtiRkGxO|RNKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSUZ|IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvOzJizszNMi=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Function assay NEmyTG1DSUZ| MmjmO|IhcHK| M{e2dGlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD60N{DPxE1w NIPFW4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Antiproliferative assay M{LySmNJVA>? NVzt[IdjPzJiaILz NGrZUFdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGNJVCClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvPDVizszNMi=> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Function assay NXnj[opUSkGIMx?= NFrRfoQ4OiCqcoO= MXnJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCDTFugUFEyQT[PIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwNUmg{txONg>? NG[4cmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Antiproliferative assay M1r3O2JCTjN? Mlz5O|IhcHK| M2jPVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IEGuNUDPxE1w MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Antiproliferative assay MV\DTG8> M2LHSVczKGi{cx?= MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFPIU{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IEOuNkDPxE1w NYm0[4RSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVA6OjJpPkK4PFUxQTJ{PD;hQi=>
Antiproliferative assay NW\LfZl{VkOLLViyNlI5 NWTH[Y51PzJiaILz M1y4dmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjVizszNMi=> NIHOSYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC5NVQzPSd-MkmwPVE1OjV:L3G+
Antiproliferative assay NFq3TFRJOjJ{OD;DVi=> MUO3NkBpenN? M17xUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSEKyNlgwS1JiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFExKM7:TT6= MkHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyOUG0NlUoRjJ7MEmxOFI2RC:jPh?=
Function assay MlvvTFIzOjh? NUnqXHBOOC53IIXN NWXEc3BHOyCqcoO= NHzreYdKdmirYnn0bY9vKG:oIFHMT{BqdiCqdX3hckBJOjJ{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IECuOUB2VSCjZoTldkA{KGi{czDifUBY\XO2ZYLuJIJtd3RibXX0bI9l NUjwcJdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwPVE1OjVpPkK5NFkyPDJ3PD;hQi=>
Function assay NGfoOohD[S:IMx?= MUGwMlEhfG9iMTD1US=> NEniTpY4OiCqcoO= NY\Q[nJXUW6qaXLpeIlwdiCxZjDoeY1idiC5aXzkJJR6eGViRV3MOEBnfXOnZDDBUGsh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygdJJwdGmoZYLheIlwdiCjdDCwMlEhfG9iMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFczKGi{czDmc4xtd3enZDDifUBu\XSqeXytN2gufGi7bXnkbY5mKGmwY3;ydI9z[XSrb36gcYVie3W{ZXSgZYZ1\XJiODDodpMh[nliZnnseIVzKHOlaX70bYxt[XSrb36gZ492dnSn NUPXRY5MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwPVE1OjVpPkK5NFkyPDJ3PD;hQi=>
Antiproliferative assay NFL6UXdMSVKSQWOyPVk> NHy1eW44OiCqcoO= MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuDUmDBV|I6QSClZXzsd{Bp[XKkb4LpcochVlCPLVHMT{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xQDdizszNMi=> NXe1RZF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO|Q5ODlpPkK5NVc1QDB7PD;hQi=>
Antiproliferative assay M3fKOGhESzd6 M1u2cFczKGi{cx?= NY\TOWIzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR2M4QCClZXzsd{Bp[XKkb4LpcochW0yFM{TBNk1TV1NzIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkG3JO69VS5? NELFWWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgxQSd-MkmxO|Q5ODl:L3G+
Antiproliferative assay MVrOR2kuUDJ{Mki= M1TKWVczKGi{cx?= M1;X[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGijcnLvdolv\yCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5{NDFOwG0v NWTYeWU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO|Q5ODlpPkK5NVc1QDB7PD;hQi=>
Antiproliferative assay MmG5UmNKNUh|MUKy NFTwVlc1QCCqcoO= M3u5U2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjhizszNMi=> NHLncos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgyPCd-MkmxO|Q5OTR:L3G+
Antiproliferative assay NY\hT297UEOFN{i= NXrWToVXPDhiaILz M1iw[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPDO|gh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKg{txONg>? Mn\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NVQoRjJ7MUe0PFE1RC:jPh?=
Antiproliferative assay NUDXR4FqTUKFMR?= MVO3NkBpenN? M2XIcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFz[my3ZTDhd5NigSxiSVO1NEA:KDBwMEGzJO69VS5? M2LnO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay NIHaN3lOU052NR?= MYO3NkBpenN? NHXlU21CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XKkbIXlJIF{e2G7LDDJR|UxKD1iMD6wNlIh|ryPLh?= MnSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEK0NVAoRjJ7MkCyOFExRC:jPh?=
Antiproliferative assay MmLhUWNHPw>? MkjpO|IhcHK| MlnORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCDbHHtZZJjdHWnIHHzd4F6KHKnbHH0bZZmKHSxIHPvcpRzd2xuIFnDOVAhRSByLkC0OUDPxE1w MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay M1;m[mE2PDl? NInTd3E4OiCqcoO= M{fGS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFz[my3ZTDhd5NigSC{ZXzheIl3\SC2bzDjc451em:uLDDJR|UxKD1iMD6xN|Q{KM7:TT6= M1rEV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay NFL1XFJJS1RzMU[= M1S4UlczKGi{cx?= NVflSZBmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGFt[W2jcnLseYUh[XO|YYmgdoVt[XSrdnWgeI8h[2:wdILvcEwhUUN3MDC9JFAvOjV|NjFOwG0v MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay NX\SeXJNW0eFN{mwNS=> MVi3NkBpenN? NYr1cnBVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTS2M4QTBzIHPlcIx{KGGodHXyJFczKGi{czDifUBCdGGvYYLicJVmKGG|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4wtKEmFNUCgQUAxNjN{MUOg{txONg>? MkXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEK0NVAoRjJ7MkCyOFExRC:jPh?=
Antiproliferative assay MnXTUmNKNUh2NkC= MlP1O|IhcHK| MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XKkbIXlJIF{e2G7LDDJR|UxKD1iMj6yOFQh|ryPLh?= M{TsdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay NFvxVWFEV0yRMkC1 MV23NkBpenN? NH;zOmxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPPUG8zODViY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGFt[W2jcnLseYUh[XO|YYmsJGlEPTBiPTCyMlQ1QSEQvF2u NGfnW|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlQyOCd-MkmyNFI1OTB:L3G+
Antiproliferative assay NHzT[YpRSzN? MljTO|IhcHK| NU[0dndRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFHsZY1iemKudXWgZZN{[XluIFnDOVAhRSB7Lke4O{DPxE1w NIrwWHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlQyOCd-MkmyNFI1OTB:L3G+
Antiproliferative assay MkDoRmFHOw>? MV:3NkBpenN? NYTVb5F3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BETDd2LWLPV|Eh[W[2ZYKgO|IhcHK|IHL5JHNTSiCxcjDDR2s5KGG|c3H5MEBKSzVyIE2gNE4xPDh4IN88UU4> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Antiproliferative assay MlLzRmFHOw>? M{DDR|czKGi{cx?= NVX6ZmNESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BGVUx2LVHMT{Bi\nSncjC3NkBpenNiYomgV3JDKG:{IFPDT|gh[XO|YYmsJGlEPTBiPTCwMlA2PzVizszNMi=> NHL5b4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay M{jVOnNWNUSKTEG= NYizZ4dwPzJiaILz M2HOO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2WtSGhNOSClZXzsd{Bp[XKkb4LpcochVlCPLVHMT{Bi\nSncjC3NkBpenNiYomgV3JDKG:{IFPDT|gh[XO|YYmsJGlEPTBiPTCwMlE2PSEQvF2u NGPUfGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay M1HKfGtCWlCDU{K5PS=> NFTpWHU4OiCqcoO= M2DUUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvOTd4IN88UU4> NG\kNJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay M3jG[m5EUS2KM{GyNi=> MUG3NkBpenN? MkXrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCxcjDDR2s5KGG|c3H5MEBKSzVyIE2gNE4{ODNizszNMi=> Mnq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
Antiproliferative assay NE\yNlFDSUZ| NWq5TIRNPzJiaILz NXu5RWpiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BGVUx2LVHMT{BNOTF7Nl2gcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwM{Sg{txONg>? NWTPSGdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Antiproliferative assay NHvQ[FZDSUZ| NHrzXXE4OiCqcoO= NHHlcWRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGVOVDRvQVzLJGcyOjB{UjDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC53NkSg{txONg>? M2nLRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Antiproliferative assay NV7ocJdISkGIMx?= NHfPbpk4OiCqcoO= MnW1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQV[zJINmdGy|IHjhdoJwemmwZzDDSFc1NVKRU{GgS|IxOzKUIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjV7NDFOwG0v NVjiTG5yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Antiproliferative assay M3jpPGJCTjN? NVizbJp4PzJiaILz MnXvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDJUFMue3SrbYXsZZRm\CCvb4Xz[UBDSUZ|IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvPjR2IN88UU4> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Antiproliferative assay MWHIR2M4QA>? NHvPOms4OiCqcoO= NHPtUVdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR|c5KGOnbHzzJIhiemKxcnnu[{BUVEN|NFGyMXJQWzFiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC56OEmg{txONg>? NGfveoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
qHTS assay NV7oeYRWXEN|Mh?= NXfRTWE1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGTDN|Ih[2WubIO= NYXaSYU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay NXW5[4VGSTZ5Mx?= MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? M2nwRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NGLWdIJU[W:|LUK= Mmr6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= NXLuRVBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay M2jtTHJF M{PuPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NUTlSpdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay MVTTT{1PNVOK MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= NXnrfWtRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay M3:5UmJVNTF{ NI\GNJdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= M1ftdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NGHxTHROTyB4MzCoOk1VTyCUKR?= NXTFXJRReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz NVzhVJVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay M4H5U25DOTZ2Mx?= MoXGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= MmfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NUfOTW9HV0iVLUWw NInEV|dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay M3LNb2xCVi13 NVvRblZueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay MmHLUmIuTUKlMR?= MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{ M4Xz[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NF3ZcG5UUy2QLWPI M3jIbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN? NX3OcIRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay M4XpR3JpPDF? NHW5RW5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= NHfQcIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay M4PRbWE3PzN? M1TqWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq NWHwWIpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay NXzMUJVOWmh|MB?= NF6yc2tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay M2n3XWJVNTN5 NEP3NGtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1|NzDj[Yxtew>? MmOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay M2TV[W1IKDZ|IDi2MXRIKFJr NFf6UodyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>? NVzOeGE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay MmDwVog{OA>? MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz MkfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MmPXU2hUNTVy MlfWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{ NV7Hc|NKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay M{OybXNLNUeETUK= NV3McnBMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> MlrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NIC1S2xUUy2QLV3D Moi1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= Mn\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NWLmNoZiVkJvRVLjNS=> MkC5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= MkPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NIDBfplNSU5vNR?= NEPXdmhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= NHfXWpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay NXrkUmpCWmhzOB?= M{nreZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy| M{G3dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NFuxO3RPSjF4NEO= NGDXSIRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSjF4NEOgZ4VtdHN? NXHiSIFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay NUjQO3JOW0tvTj3NRy=> NHzhXm1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy| M1TPU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay M4\HfXREOzJ? NEi4XGRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{ M3zGR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NWfXZ2RNWmhzOB?= Mn7TdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=> M3yxPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay MmLiV4Fwey1{ NIDCSGZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:|LUKgZ4VtdHN? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Antiproliferative assay NX\OT2RlTUKFMR?= MnvmO|IhcHK| NVnjWoFXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtKFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFAvODN7IN88UU4> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZyMkCzOkc,Ojl4MEKwN|Y9N2F-
Function assay NEjnUIlJezV5OGS= NIXyV4kyODBibl2= MYizNEBucW6| M3nvU2lvcGmkaYTpc44hd2ZiaHXwd4lvNW2nZHnheIVlKGOxbo\ldpNqd25ib3[gVJJwNUiJRjDpcpRwKGGldHn2[UBnd3KvIHnuJIh2dWGwIFjzOVc5XCClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDNSXQheGixc4Doc5J6dGG2aX;uJIF1KDFyMDDuUUBxemWrbnP1ZoF1\WRiZn;yJFMxKG2rboOg[o9tdG:5ZXSgZpkhemWlb33ibY5idnRiaIXtZY4heHKxLVjHSkBi\GSrdHnvckBu\WG|dYLl[EBi\nSncjCzNEBucW6|IHL5JIludXWwb3Lsc5QhdQ>? M2qx[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{CxPVYzLz5{OUewNVk3OjxxYU6=
Function assay NHT3dJBJS0NzOUO3 MYexNFAhdk1? NH7aPGQ{OCCvaX7z MoTTTY5pcWKrdHnvckBw\iCqZYDzbY4udWWmaXH0[YQh[2:wdnXyd4lwdiCxZjDQdo8uUEeIIHnueI8h[WO2aY\lJIZwem1iaX6gbJVu[W5iSFPDNVk{PyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDNSXQheGixc4Doc5J6dGG2aX;uJIF1KDFyMDDuUUBxemWrbnP1ZoF1\WRiZn;yJFMxKG2rboOg[o9tdG:5ZXSgZpkhemWlb33ibY5idnRiaIXtZY4heHKxLVjHSkBi\GSrdHnvckBu\WG|dYLl[EBi\nSncjCzNEBucW6|IHL5JIludXWwb3Lsc5Q> M3e2RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{CxPVYzLz5{OUewNVk3OjxxYU6=
Antiproliferative assay NXPJe2RlVkOLLViyNlI5 MUW3NkBpenN? M2OzWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGijcnLvdolv\yCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yOEeg{txONg>? MnTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MkOxNlAoRjNyMkKzNVIxRC:jPh?=
Antiproliferative assay M37JXWhESzd6 M1\YRVczKGi{cx?= NG\6cJRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR|c5KGOnbHzzJIhiemKxcnnu[{BUVEN|NFGyMXJQWzFiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUeg{txONg>? NX;tcW5WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>
Antiproliferative assay NYLP[2pCU0GUUFHTNlk6 NWG3bFJXPzJiaILz NYfST3ZzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiaHHyZo9zcW6pIF7QUU1CVEtiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMkSg{txONg>? MmG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MkOxNlAoRjNyMkKzNVIxRC:jPh?=
NB1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHVVpptUUN3ME25NU46QCCwTR?= M1m4VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NCI-SNU-5 NWDBSoxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Ls[2lEPTB;MUC1Mlc2KG6P NH3Pd|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
SR NXTGUWRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\0TWlEPTB;MUK2MlMyKG6P M{n4RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SF539 Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofPTWM2OD1{MESuNlQhdk1? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SU-DHL-1 Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLrTWM2OD1|M{[uPFIhdk1? MljZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
SCC-3 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\YTWM2OD1|NU[uO|Yhdk1? MkT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
DEL NEnBbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTN4OT65JI5O MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CTV-1 NFzZUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTV7Nj60PEBvVQ>? NUXmfodDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
EM-2 NWDnPWlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzKTWM2OD14MEGuN|Qhdk1? NFTMcGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
MHH-CALL-2 NEe2O5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HDOGlEPTB;NkiyMlU4KG6P MmfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KM12 NGnnV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTtTWM2OD15ME[uPUBvVQ>? NFjaWJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
KINGS-1 NF;lfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTd2OT63OUBvVQ>? M{O1VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MEG-01 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;OZXhKSzVyPUi1O{43PiCwTR?= NHPQ[3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
BV-173 M1TUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nMW2lEPTB;MT6wOVk6PyEQvF2= MnfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
LAMA-84 NEHjWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFwM{iyPFIh|ryP MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KARPAS-299 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHBTWM2OD1zLkSwPFYyKM7:TR?= M{DjOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
K-562 M3fheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwN{KyOlkh|ryP NV;0PINmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SK-LMS-1 M3mw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[zTWM2OD1zLke2PFY4KM7:TR?= NXjJdZBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
MOLT-16 M3OzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX2XoFKSzVyPUGuPVU2PzVizszN MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CMK MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLzTWM2OD1zLkm2NVU6KM7:TR?= M3TaflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
ST486 M2K5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HyTmlEPTB;Mj60N|A4OyEQvF2= NXr2TJg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
CI-1 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfOXoR1UUN3ME2yMlQ6PjV7IN88US=> M1LvZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
KP-N-RT-BM-1 Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TuemlEPTB;Mj63NFEzOiEQvF2= NE\ITZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
ALL-PO M2W1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7acIxKSzVyPUOuNVgzODdizszN MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KS-1 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HHc2lEPTB;Mz6yNVIzPSEQvF2= M1LmRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
Becker MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTRwMkO5N{DPxE1? NULTV251RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
GDM-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRwMkS2NVch|ryP M3LnTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
BC-1 NXXNb5VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGzTWM2OD12LkS5Nlc4KM7:TR?= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NB14 NYjveJQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwOEO1NlQh|ryP MnPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NOS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm0UmRHUUN3ME21MlM{QDd2IN88US=> NUS5dYpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
MZ1-PC MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDNVmFKSzVyPUWuPFIyPTFizszN NYf2SJRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
A498 M3\Od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L4UmlEPTB;Nj6wPFQ4OyEQvF2= M4HOe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
EW-16 NYDQZmMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHro[YVKSzVyPU[uN|c4PzNizszN NXLEWYJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NALM-6 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjYVGRKSzVyPU[uOlg{QDdizszN MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
EB-3 M3rQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TBU2lEPTB;Nz6wO|I{OyEQvF2= Mm\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
697 MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33rO2lEPTB;OT6yOFMzQSEQvF2= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10 NIrqbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTnbpdvUUN3ME25MlU6QDR{IN88US=> NH\ReWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
KNS-81-FD M1\uXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDBOGVmUUN3ME25MlY6PjV|IN88US=> M4DtblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
HUTU-80 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDMUHNKSzVyPUmuO|Q3PDJizszN NYrqbHgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
LS-411N M3HnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nKN2lEPTB;MUCuNFU3PyEQvF2= NHHoUlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
RPMI-8402 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLyflRKSzVyPUGwMlEyPiEQvF2= NVrDTG44RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
KU812 NIHIXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS5[mxyUUN3ME2xNE4zQTlzIN88US=> NG[0ToI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
EW-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XlcGlEPTB;MUCuOFQzPSEQvF2= M1HwZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
HC-1 M1LYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj3VFRHUUN3ME2xNE41QDR2IN88US=> NWPOVoZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NB69 M3eyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTCdI1nUUN3ME2xNE42ODR|IN88US=> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MFH-ino NG[4XWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFyLkizNFMh|ryP MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CCRF-CEM NVrCOm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPLTWM2OD1zMT61PVch|ryP MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SK-N-DZ NGW2VHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTTZ3VKSzVyPUGyMlA1OzZizszN NVjsPY1DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NCI-H720 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13YOWlEPTB;MUKuNVcxPSEQvF2= NYq4R|VORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HCC1187 MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHQTWM2OD1zMj6yNFQyKM7:TR?= NGG5XpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
IST-SL2 NGrteXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXTTWM2OD1zMj60PFczKM7:TR?= M{[0e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
KE-37 NVi2V|lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn6WHRmUUN3ME2xNk44QTZ4IN88US=> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
HCC1599 NX;lUnp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6yc2xKSzVyPUGyMlkxPjlizszN M2XYPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
A4-Fuk MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX35ZmR4UUN3ME2xNk46PTh4IN88US=> M13xSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NKM-1 NWn5TlQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnPVm1KSzVyPUGzMlI6OjVizszN NIHyeIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
BE-13 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLBN3FKSzVyPUGzMlc6QDlizszN MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MV-4-11 NIX3TXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3ldGFKSzVyPUG0MlA{OjRizszN MlPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
OPM-2 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDnTWM2OD1zND60NFg2KM7:TR?= MkL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KARPAS-422 M3\hOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF2LkWxNlYh|ryP NXO1VI1qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
RPMI-8226 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF2Lki5NVUh|ryP NHLlXoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
KARPAS-45 M2XXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF3Lke3NVYh|ryP MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SK-PN-DW MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;HR3FKSzVyPUG1Mlg3OzFizszN M3y0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LC-2 NVfGZYt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\kSGlEPTB;MU[uNVUxPiEQvF2= M2mxXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NCI-H1648 NV;XSoFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW5TWM2OD1zNj6yOVQh|ryP MlX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
RL95-2 NWHDSnVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTaTWM2OD1zNj6zPVc5KM7:TR?= MkjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KNS-42 M4rkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MornTWM2OD1zNj63Nlc1KM7:TR?= M4jqfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
RPMI-6666 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorTTWM2OD1zNj65NlEyKM7:TR?= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SIG-M5 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\QOmlEPTB;MUeuNVkxOyEQvF2= M{K5RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
VA-ES-BJ NXXLbZhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHqTWM2OD1zNz63OFUyKM7:TR?= MmDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MONO-MAC-6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF5LkmzNVIh|ryP M3:2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LAN-6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn4TWM2OD1zOD63OVU4KM7:TR?= NUmxNWZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
A388 MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS4TWM2OD1zOT6zNFU6KM7:TR?= M4r0V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SK-NEP-1 M1Hjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPxd|BKSzVyPUKwMlIyOzJizszN M2TqU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
TE-10 NVPLNoJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DUSWlEPTB;MkCuOVIzOSEQvF2= NVGzTlV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HL-60 M3OzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljRTWM2OD1{MD65NFk6KM7:TR?= NVzGc2cyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
MC116 NYPPbZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nJR2lEPTB;MkGuO|IzOSEQvF2= M3u2d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SW962 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK3T3ZKSzVyPUKxMlc6OTVizszN M3vRcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NOMO-1 Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlriTWM2OD1{Mj62OVY1KM7:TR?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CTB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m4e2lEPTB;MkKuPFY4OSEQvF2= MnfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MRK-nu-1 NWfmUoROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJ{LkmwO|Qh|ryP M{[2S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
GR-ST MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLFcYxKSzVyPUKzMlc3KM7:TR?= NYnF[o42RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HH NGG4NmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ2LkCwN{DPxE1? MoS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-H1963 M4rlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPTRnNKSzVyPUK0MlA4QDJizszN MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
QIMR-WIL M3zLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13EOGlEPTB;MkSuPFc4OiEQvF2= NVLFVoxiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
CGTH-W-1 M3PFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf1e3FKSzVyPUK1MlA4OjNizszN MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
LP-1 NVHkTpd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPTdFlNUUN3ME2yOU43PTVzIN88US=> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H748 M1;vR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfFZXRKSzVyPUK2MlUyOzdizszN NYHYUpR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
PF-382 NXfHVm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvSfWdKSzVyPUK3MlIzOjNizszN M2LFeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
ATN-1 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;Q[G5UUUN3ME2yO{4{PzN{IN88US=> MnrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
L-540 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[3TWM2OD1{Nz62OFU6KM7:TR?= M1rmeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LXF-289 NX75NWY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH3XZp6UUN3ME2yO{44PTF7IN88US=> M2HWW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LS-513 NHLSNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fnUWlEPTB;MkiuNVgxPyEQvF2= MnX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-H1581 NV\ucZdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNyLkO5O|Yh|ryP M1LMUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
ES6 NVPrOJF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzS[odKSzVyPUOwMlY5QTlizszN M1fZRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SW982 NEXNdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XhXmlEPTB;M{CuPFU3PiEQvF2= M2X2d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
DOHH-2 NE\XWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:wN2lEPTB;M{GuOVg6OyEQvF2= NEPiS5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
DB MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXxeHVKSzVyPUOzMlk1OzFizszN M4HBNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MPP-89 M2PCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi1SlRKSzVyPUO0MlE4PTZizszN MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
LB831-BLC M3vrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TVZWlEPTB;M{SuOVE5PCEQvF2= NHq1bpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
NB5 M1nmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN2Lki1N|Uh|ryP M3rpeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
GB-1 NHewRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLyXnFKSzVyPUO1MlA1PjlizszN NEDuZZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
TE-15 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXaTWM2OD1|NT6yNlM5KM7:TR?= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
LC4-1 M3:xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPiRmRKSzVyPUO1MlM5PDdizszN Ml\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-H747 NGnOXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTHVZJKSzVyPUO2MlE{PjlizszN NH;4T3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
NTERA-S-cl-D1 M2O3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq2XGllUUN3ME2zPE44OzR5IN88US=> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SK-MM-2 NHyyeJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj2eItqUUN3ME20NE4yOTR4IN88US=> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
TGW MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H0OGlEPTB;NEGuNFU3OyEQvF2= MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
ONS-76 MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR{LkS4PFMh|ryP MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CPC-N NXLsXYRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTR{Lkm5O|Eh|ryP NFWyO2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
ES4 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR2LkSxOVMh|ryP NWDtUG81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
Daudi M2HWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHVeVgxUUN3ME20OU4xQDJ5IN88US=> MkXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MOLT-4 NFuxWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[yNlRKSzVyPUS1MlA5PTNizszN NFjpd489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK|5USU6JRWK8M4E,
HT-144 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M134T2lEPTB;NE[uO|I3KM7:TR?= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SW872 NF\GNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf2UGZVUUN3ME20PE4yQTN|IN88US=> MoLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
D-283MED NWDSN|F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv1NmVxUUN3ME20PE4{PTR{IN88US=> NWnGOXZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NCI-H2126 M2LiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTR6Lki0O|Yh|ryP NVriNIRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NCI-SNU-16 M2jpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfv[nNKSzVyPUS5MlIyPDNizszN MkTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CESS M2TyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHrTWM2OD12OT61NFg5KM7:TR?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
A101D MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHVU2NKSzVyPUS5Mlk4OzZizszN MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pALK / pAKT / pERK / pS6; 

PubMed: 24675041     


H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins.

pROS1 / ROS1; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

pSTAT3 / STAT3; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

PARP / cleaved caspase-3 / Bax / Bcl-2; 

PubMed: 25193856     


The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr.

p-c-Met / c-Met; 

PubMed: 25193856     


Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification).

p-mTOR; 

PubMed: 26384345     


Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.

24675041 25351743 25193856 26384345
Immunofluorescence
LC3 / lysosome; 

PubMed: 26384345     


Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. 

SRC / Met; 

PubMed: 26517812     


Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

α-tubulin; 

PubMed: 26517812     


LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

cytochrome c; 

PubMed: 25193856     


PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red

p-ALK; 

PubMed: 25193856     


PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.

26384345 26517812 25193856
In vivo

In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

- Collapse

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

- Collapse
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A
Smiles CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04148066 Recruiting Diagnostic Test: ctDNA blood sample Carcinoma Non-Small-Cell Lung The Netherlands Cancer Institute|Roche Pharma AG July 17 2019 Not Applicable
NCT03947385 Recruiting Drug: IDE196|Drug: Binimetinib|Drug: Crizotinib Metastatic Uveal Melanoma|Cutaneous Melanoma|Colorectal Cancer|Other Solid Tumors IDEAYA Biosciences June 28 2019 Phase 1|Phase 2
NCT03439215 Active not recruiting Drug: Lorlatinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale|Clinical research technology Srl June 13 2017 Phase 2
NCT02946216 Unknown status Genetic: ctDNA analysis Non-small Cell Lung Cancer Stage III|Non-Small-Cell Lung Cancer Metastatic|Adenocarcinoma of Lung|EGFR Wildtype First People''s Hospital of Hangzhou November 2016 --
NCT02511184 Terminated Drug: Crizotinib|Drug: Pembrolizumab ALK-positive Advanced NSCLC Pfizer|Merck Sharp & Dohme Corp. October 2015 Phase 1
NCT02419287 Active not recruiting Drug: crizotinib Anaplastic Large Cell Lymphoma ALK-Positive University of Milano Bicocca April 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID